Chronic hepatitis B (CHB) exhibits a variety of clinical outcomes, ranging from spontaneous resolution of hepatitis B to severe adverse consequences, including the development of cirrhosis, hepatic failure, and hepatocellular carcinoma. The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex host-virus interactions, and point to the difficulty and necessity of identifying the patients at risk. With the advance of HBV virology, several viral factors have been found to be associated with the long-term clinical outcomes of CHB patients. Different viral factors probe different aspects of CHB. Integration of these viral factors may help to determine the disease state of patients more accurately, and identify the patients who require timely antiviral therapy to prevent the development of detrimental clinical outcomes. In this article, we will introduce the conventional and emerging viral factors that are associated with clinical outcomes and discuss their utility in a clinical setting.
Hepatitis B virus (HBV) infection remains a challenging issue
of global public health. Since the introduction of HBV vaccination, the risk of transmission, including vertical mother-to-child transmission and horizontal transmission, has decreased dramatically. However, it is estimated that 248 million persons are still chronically infected by HBV worldwide [1] . This imposes a high socioeconomic burden in the endemic regions and countries. The clinical outcomes of chronic hepatitis B (CHB) vary greatly, ranging from spontaneous resolution of hepatitis B to severe detrimental consequences, including the development of hepatic failure, cirrhosis, and hepatocellular carcinoma (HCC) [2] . Persistent or recurrent hepatic necroinflammation mediated by the host antiviral immunity is the major cause for the disease progression, eventually leading to advanced fibrosis and carcinogenesis of liver. The lifetime risk of severe adverse outcomes of CHB is as high as 15%-40% [2] [3] [4] [5] . Early diagnosis and timely antiviral treatment for those at risk are required to prevent the development of adverse clinical outcomes. Several conventional and novel host and viral factors have been associated with the disease progression and clinical outcomes of CHB. Here we will only focus on the role of viral factors affecting the disease progression.
Viral Proteins and Replication Cycle of HBV
The molecular biology of HBV infection has been extensively reviewed elsewhere [6] . We will only highlight some virological issues relevant to clinical importance of viral factors. HBV belongs to the family Hepadnaviridae, and has a circular partially double-stranded DNA (pdsDNA) genome with the size of 3.2 kb, encoding 4 open reading frames: core, polymerase, surface and X. HBV genomes produce 7 major viral proteins, including hepatitis B e antigen (HBeAg), core protein, 3 forms (large, middle, and small) of hepatitis B surface antigen (HBsAg), polymerase, and hepatitis X protein (HBx). Both core and polymerase proteins are essential for HBV replication. Core protein, also known as hepatitis B core antigen (HBcAg), is a structural protein and can assemble into core particles containing HBV genomes inside. The large, middle, and small HBsAgs are the 3 components of HBV envelope proteins. The large and middle HBsAgs contain the extra amino-terminal extensions (PreS1 and PreS2 regions) of the small HBsAg. The functions of HBeAg and HBx have been elusive until recently. HBeAg shares a large number of identical amino acid residues with HBcAg and has the amino-terminal extension (precore domain) and carboxylic-terminal processing. Unlike HBcAg as a structural unit, HBeAg is a secretory protein. Although the biological role of HBeAg is not fully understood, it is generally assumed that HBeAg probably acts as a tolerizing agent to impair the host immune response targeting HBcAg [7] . A recent study in a murine model also supports the role of intrauterine HBeAg in dampening the anti-HBV immune response during the perinatal transmission route [8] . HBx has been suggested to contribute to the HBV-induced carcinogenesis [9] . Recently, it has been found that HBx promotes the transcription of covalently closed circular DNA (cccDNA) by destroying the smc5/6 complex through cellular DDB1-containing E3 ubiquitin ligase [10] .
HBV infects hepatocytes through the binding of the large HBsAg to the recently discovered receptor sodium taurocholate cotransporting polypeptide receptor [11] . Upon entry, the virions are uncoated and then translocated into the nuclei of infected hepatocytes in which the pdsDNA genome, also known as relaxed-circular DNA, is converted to cccDNA [12] [13] [14] . HBV cccDNA serves as the replicative template and transcribes viral mRNAs including the pregenomic RNA, which undergoes reverse transcription to form the pdsDNA inside the viral capsids in cytoplasm. Mature capsid containing the pdsDNA genome is either enveloped by viral surface proteins in endoplasmic reticulum and secreted as a virion or is recycled back to the nuclei to supply the cccDNA pools. Occasionally, HBV genomes undergo in situ priming to form double-strand linear DNA, and are integrated into host genomes. Analysis of integrated HBV genomes in HBVrelated hepatoma cells revealed that the integration breakpoints are randomly distributed across the entire HBV genomes with a number of hotspots [15] . Besides, most integrated HBV DNAs contain partial genomes rather than full-length ones. Therefore, integrated HBV genomes are defective in production of pgRNA, but are probably a source of some viral proteins, like HBsAg.
Natural History of CHB
Following exposure to HBV, a portion of infected persons eventually resolve the acute hepatitis B virus infection, but others will become chronically infected, defined by the persistence of HBsAg for >6 months. The rate of HBV chronicity is directly related to the exposure age of patients, from >90% in infants to 5% in adults [2, 16] . In the Asia-Pacific region, HBV infection is primarily through the vertical mother-to-child transmission that occurs during the perinatal period, so infants born to HBsAg-positive mothers are at high risk for the development of chronic HBV infection [17] .
The natural course of CHB varies greatly among infected individuals and evolves along with time. Based on the alanine aminotransferase (ALT) level, HBeAg serostatus, HBV DNA level, and liver histology, the natural history of CHB is conventionally divided into 4 distinct phases: immune tolerance, immune clearance, inactive carrier, and HBV reactivation [18] . The immune-tolerance phase is mostly seen in children who acquire the infection at a young age, and lasts for 1 or 2 decades. In the first immune-tolerance phase, HBsAg carriers are positive for HBeAg and have a very high HBV DNA level, normal ALT, and no or minimal liver injury. The breakdown of immune tolerance usually occurs during adolescence and early adulthood, and is evidenced by hepatitis flares and declined HBV DNA, signifying the transition from immune tolerance to the immune clearance phase. Although the mechanisms causing the loss of immune tolerance remain unclear, it is generally assumed that activation of the seemingly dormant anti-HBV immune responses plays a role. In Asia, the majority (90%) of patients undergo HBeAg seroconversion by the age of 40, and eventually turn into an inactive carrier state (the third phase), defined by normal ALT and low viral replication (HBV DNA < 2000 IU/mL). However, some patients with HBeAg seroconversion suffer from HBV reactivation and hepatitis flares (the fourth phase), called HBeAg-negative hepatitis. Prolonged immune clearance phase and HBeAg-negative hepatitis with persistent or recurrent hepatitis flares will eventually result in advanced liver fibrosis or even cirrhosis and increase the risk of HCC. Therefore, antiviral therapy is recommended for these 2 patient groups by all current clinical guidelines [19] [20] [21] . Recently, this conventional view of the natural history of CHB has been challenged. Because of the important role of liver inflammation (hepatitis) in the disease progression of chronic HBV infection, European Association for the Study of the Liver 2017 clinical practice guidelines for HBV infection have suggested a new nomenclature for the natural history of CHB based on 2 main characteristics of chronicity, infection and hepatitis [21] . According to this new nomenclature, HBeAg-positive chronic HBV infection, HBeAg-positive chronic hepatitis B, HBeAgnegative chronic HBV infection, and HBeAg-negative chronic hepatitis B have replaced the conventional terminology immune tolerant, immune clearance, inactive carrier, and HBV reactivation phases, respectively. Nevertheless, the conventional terminology is still adopted by the American Association for the Study of Liver Diseases and Asian Pacific Association for the Study of the Liver guidelines [19, 20] .
Of note, a portion of HBeAg-negative inactive carriers will finally lose HBsAg. HBsAg loss is an indicator of resolution of HBV infection, and often confers a favorable clinical outcome as long as no cirrhosis develops at the time of HBsAg loss. However, among those with HBsAg loss or seroconversion, some patients still have detectable HBV DNA in serum or liver, and are considered as occult HBV infection. They still harbor replication-competent HBV genomes in liver. This is supported by the fact that HBV reactivation occurs when these patients receive intensified chemotherapy.
Viral Factors and the Disease Progression of CHB
Although the conventional view of the natural history of CHB based on the ALT level, HBeAg, and HBV DNA levels is useful to determine the disease state of patients, this approach is somehow too simplified to cope with the various clinical courses and outcomes of CHB. In addition to the serostatus of HBeAg and HBV DNA level, several other viral factors have been associated with the disease progression, including serum HBsAg level, HBV genotype, HBV mutants, hepatitis B core-related antigen (HBcrAg) level, and anti-HBcAg level. Each viral factor may probe a unique virological aspect, and combinatorial use of a set of viral factors may help define the stage of the disease more precisely. Early identification of HBsAg carriers at risk of disease progression can help to provide them with the timely and appropriate antiviral treatment and prevent the long-term detrimental clinical outcomes. We will introduce these viral factors and provide evidence of current studies below. The virological features and interpretation of these viral factors and their impact on disease progression are also summarized in Table 1 .
The serostatus of HBeAg has been an important biomarker for the natural history of CHB. The HBeAg positivity indicates active viral replication. Earlier HBeAg seroconversion usually confers a favorable clinical outcome of CHB patients. A large Taiwanese community-based cohort study recruiting 11 893 men at age >30 years showed that the HBeAg positivity at entry of study was associated with higher risk of HCC. Compared with those negative for both HBsAg and HBeAg, the relative risk of HCC is 9.6 among men positive for HBsAg and negative for HBeAg, and 60.2 among those positive for both HBsAg and HBeAg [22] . This clearly demonstrates that the positivity of HBeAg is associated with the development of HCC.
Quantitative HBeAg levels have been shown to be associated with the response to antiviral therapy with pegylated interferon and nucleos(t)ide analogues (NAs) [23, 24] . The continuous on-treatment decline of HBeAg levels predicted HBeAg loss or seroconversion. In treatment-naive HBsAg carriers, the HBeAg level is correlated with the HBV DNA level, but this correlation is affected by the emergence of precore and basal core promoter (BCP) mutations [25] . Although HBeAg serostatus is associated with an increased risk of HCC, the role of HBeAg levels in the adverse outcomes of CHB remains unclear.
HBV DNA Levels
HBV replicates at a very high rate. HBV replication is considered the primary driving force for disease progression. The serum HBV DNA level is a marker of HBV replication. Several prospective studies have shown that HBV DNA levels are associated with the risk of HCC in CHB patients [26] [27] [28] [29] . The large community-based Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study that enrolled HBsAg carriers aged 30-65 at entry in Taiwan elegantly demonstrated that HBV DNA levels were associated with the risk of HCC, cirrhosis, and HBV-related mortality [28, 30, 31] . Among patients with HBV levels ranging from 300 copies/mL to 1 million copies/mL, the cumulative incidence rates of HCC were 1.3% and 14.9%, respectively, and the cumulative incidence rates of cirrhosis ranged from 4.5% to 36.2%.
However, a high HBV DNA level does not necessarily lead to adverse clinical outcomes. Of note, the disease progression of HBsAg carriers in a persistent immune-tolerant phase seems HBeAg levels correlate with serum HBV DNA levels, but this correlation is affected by the emergence of precore and BCP mutation.
HBeAg positivity is associated with a higher risk of HCC [22] . On-treatment decline of HBeAg levels predicts NA or IFN-induced HBeAg loss/SC [23, 24] .
HBV DNA The serum HBV DNA level is a marker of HBV replication, which is the primary driving force for disease progression.
High HBV DNA levels are associated with the increased risk of cirrhosis [30] , HCC [26] [27] [28] [29] , and HBV-related mortality [31] .
HBsAg level HBsAg mRNA is transcribed from cccDNA and integrated HBV genomes. HBsAg level correlates well with serum HBV DNA and intrahepatic cccDNA levels in HBeAg-positive patients, but not in HBeAgnegative patients.
In HBeAg-negative HBV carriers, low HBsAg levels were associated with HBsAg loss [38, 44] . In patients with low viremia (<2000 IU/mL), higher HBsAg level predicts the risk of disease progression [45, 46] . Combinatorial use of HBV DNA <2000 IU/mL and HBsAg <1000 IU/ mL can help to identify truly inactive carriers and patients with a minimal risk of HCC [43, 47] .
HBV genotype HBV genotypes are defined by >8% difference in the complete genome sequences, and are distributed along with different geographic areas and ethnic populations.
Genotype C tends to have absence or delay of HBeAg seroconversion [50, 52] . Genotype A > genotype D and genotype B > genotype C in HBsAg seroclearance [52, 53] . Genotypes C and F > genotypes A, B, and D in risk of HCC [50] . Genotype C > genotype B in risk of HCC [55, 56] . Viral mutants The precore G1896A results in the premature translational termination of precore protein, causing the loss of HBeAg. The dual BCP mutations A1762T and G1764A affect the transcription of precore mRNA and reduce the production of HBeAg. The pre-S deletion leads to accumulation of large surface protein in the ER, which causes ER stress and hepatocarcinogenesis.
Precore and BCP mutations are associated with higher chance of HBeAg seroclearance/seroconversion [60] [61] [62] [63] [64] [65] . BCP mutation is associated with the increased risk of cirrhosis and HCC [54, 56, [69] [70] [71] [72] [73] [74] . PreS deletion is associated with the increased risk of HCC [78, 79] .
HBcrAg
HBcrAg measures the levels of HBcAg, HBeAg and p22cr simultaneously. HBcrAg level correlates well with serum HBV DNA and the intrahepatic cccDNA level, so is a good marker for the transcriptional activity of cccDNA.
HBcrAg levels in natural history of CHB: immune-tolerance phase > immune clearance phase > HBeAg-negative hepatitis > HBeAgnegative quiescent/inactive carrier phase [86, 87] . High HBcrAg is associated with the increased risk of HCC [88] .
qAnti-HBc qAnti-HBc levels are positively correlated with ALT levels, and may reflect the immune response against HBV.
qAnti-HBc in natural history of CHB: immune clearance and HBeAgnegative hepatitis > immune clearance and inactive carrier > occult HBV infection > past HBV infection [91, 92] .
to be very slow. In a prospective study with a cohort of 57 immune-tolerant CHB patients at the median age of 31, paired liver biopsy showed the negligible fibrosis progression in 48 patients who had normal ALT and remained in the immune-tolerant phase [32] . Therefore, a prospective study with a large cohort is required to further investigate the long-term prognosis of CHB patients in a truly immune-tolerant phase.
HBsAg Serostatus and Level
HBsAg is a conventional marker for the infection of HBV; persistence of HBsAg >6 months indicates the chronicity of HBV infection. In the natural history of CHB, HBsAg loss or seroconversion represents the resolution or a functional cure of hepatitis B, and often confers a favorable clinical outcome in patients without advanced fibrosis or cirrhosis. Previous longitudinal studies reported that the annual rate of HBsAg loss is 0.5%-2.3%, which varies depending on the age at study entry and disease status [33] [34] [35] [36] [37] [38] . Recent development of quantitative HBsAg assays allows for measurement of HBsAg levels. HBsAg levels have been shown to be associated with disease status [39] [40] [41] [42] , ranging from highest in the immune-tolerant phase to lowest in an inactive carrier state. In addition, HBsAg level correlates well with serum HBV DNA and intrahepatic cccDNA levels in HBeAg-positive patients, whereas in HBeAg-negative patients, HBsAg correlates poorly with serum HBV DNA and did not correlate with intrahepatic cccDNA [25] . A previous study also showed that the combinatorial use of HBsAg (<1000 IU/mL) and HBV DNA (≤2000 IU/mL) can identify inactive carriers of genotype D more accurately [43] .
The HBsAg level is suggested to predict HBsAg loss, disease progression, and the risk of HCC. A recent hospital-based cohort study on 390 spontaneous HBeAg seroconverters, primarily with genotype B or C infection, showed that low serum levels of HBsAg at 1 year after HBeAg seroconversion was associated with HBsAg loss [38] . Besides, in HBeAg-negative HBV carriers, low HBV DNA level (<2000 IU/mL) and HBsAg level <10 IU/mL were associated with HBsAg loss [44] . Moreover, in patients with low viremia (<2000 IU/mL), higher HBsAg level predicts the risk of disease progression, including hepatitis flares, HBeAg-negative hepatitis, and cirrhosis [45, 46] . The annual incidence of HBeAg-negative hepatitis was as low as 1.1% in patients with low levels of HBV DNA, HBsAg, and ALT, so combinatorial use of HBsAg <1000 IU/mL, low levels of HBV DNA, and ALT helps to define minimal-risk HBV carriers. More importantly, among HBeAg-negative patients with genotype B or C infection and low viremia (<2000 IU/mL), the adjusted hazard ratio for HCC in patients with levels of HBsAg ≥1000 IU/mL was 13.7 compared with those <1000 IU/mL. Therefore, combinatorial use of HBV DNA <2000 IU/mL and HBsAg <1000 IU/mL can help to identify patients with a minimal risk of HCC [47] .
HBV Genotype
Phylogenic analysis of HBV genomes has shown there are currently at least 10 different genotypes, A to J, which are defined by >8% difference in the complete genome sequences. HBV genotypes are distributed along with different geographic areas and ethnic populations. Genotype A is widespread in Northern Europe, Western Africa, and sub-Saharan Africa. Genotypes B and C are prevalent in Asia. Genotype D is common in Europe, the Mediterranean region, Africa, and India. Genotype E is primarily found in West Africa [48] . Genotype F is reported in South America and the Arctic Circle [49] . Genotype G has been found in France, Germany, and the United States. Genotype H exists in Central America. Of note, the association among genotypes, geographic regions, and ethnicities has somehow confounded the studies on the role of HBV genotype in the disease progression. Nevertheless, several studies have demonstrated that different genotypes are related to distinct disease progression and clinical outcomes.
A prospective cohort study in Alaska that enrolled 1158 HBsAg carriers with genotypes A, B, C, D, and F found that individuals with genotype C achieved HBeAg seroclearance at an older age, and genotypes C and F were associated with HBeAg reversion after HBeAg seroclearance [50] . Compared with genotype B, genotype C infection was more likely to have absence or delay of spontaneous HBeAg seroconversion [51] . A longitudinal study recruiting 258 Spanish patients with genotypes A, D, and F infection reported that genotype A was associated with a higher rate of sustained remission after HBeAg seroconversion than genotype D, although the HBeAg seroconversion rate was unrelated to HBV genotype [52] . Moreover, the rates of HBsAg seroclearance were higher in genotypes A and B infection than those in genotypes C and D infection [52, 53] . HBV genotype has also been shown to be associated with the risk of cirrhosis and HCC [54] . Compared with genotype A infection, genotype D infection is associated with more severe liver injury and advanced liver fibrosis. Besides, several previous studies have demonstrated that genotype C infection was associated with the risk of cirrhosis and HCC compared with genotype B infection [55] [56] [57] [58] . Interestingly, several studies showed that genotype C infection was associated with the development of HCC at older age, whereas genotype B infection was associated with an increased risk of early-onset HCC [51, 55] .
HBV Mutants
HBV has an error-prone polymerase that lacks the proofreading ability. Therefore, viral mutants frequently emerge during the long course of chronic HBV infection and form quasispecies in an infected individual. Several HBV mutations have been associated with different clinical outcomes. Here we only focus on 3 common naturally occurring mutants, including precore, BCP mutations, and preS deletion. The precore stop codon G1896A results in the premature translational termination of precore protein, causing the loss of HBeAg. The dual BCP mutations A1762T and G1764A affect the transcription of precore mRNA and reduce the production of HBeAg [59] . Both the precore and BCP mutations have been associated with HBeAg seroconversion [60] [61] [62] [63] [64] [65] . Consistently, quantitative analysis of precore and BCP mutants also demonstrated that the percentage of the precore and BCP mutations gradually increased during HBeAg loss or seroconversion [66, 67] .
However, several lines of evidence suggest that precore and BCP mutations in CHB may have different biological effects. Previous study found that the dual A1762T/G1764A (TA) mutations in combination with T1753A and T1768A contribute to the development of HCC by dysregulation of cell cycle through upregulation of SKP2 and downregulation of p21 [68] . Several previous studies showed that BCP mutations, but not precore mutation, were strongly associated with liver inflammation and the risk of cirrhosis and HCC [54, [69] [70] [71] [72] [73] . In the community-based REVEAL-HBV cohort study, BCP mutations were associated with the increased risk of HCC with adjusted hazard ratio (aHR) of 1.73, whereas the precore mutation reduced the risk of HCC (aHR, 0.34) [56] . A meta-analysis of 43 studies, including 40 case-control studies and 3 cohort studies, also showed that BCP mutations, but not precore mutation, were associated with the risk of HCC (odds ratio, 3.79) [73] . In a recent hospital-based cohort (ERADICATE-B [elucidation of risk factors for dIsease control or advancement in Taiwanese hepatitis B carriers]) study, quantitative analysis of the precore and BCP mutations demonstrated that patients with higher percentage of the BCP mutation, but not the precore mutation, at 1 year after HBeAg seroconversion exhibited higher risk of cirrhosis, further supporting the adverse effect of BCP mutations in disease progression [74] .
The PreS deletion frequently emerges during chronic HBV infection, and probably results from the selection pressure imposed by the antiviral immune responses [75, 76] . The deletion over pre-S gene can lead to accumulation of large surface protein in the endoplasmic reticulum (ER), which causes ER stress and hepatocarcinogenesis. In addition, preS2 protein has been shown to promote HCC development via its transcriptional activation of hTERT [77] . PreS deletion has also been associated with the risk of advanced liver disease and HCC in HBeAg-negative patients [78, 79] .
HBcrAg
HBcrAg measures the levels of HBcAg, HBeAg, and a 22-kDa precore protein without C-terminal arginine-rich domain (p22cr) simultaneously [80, 81] . Previous studies showed that HBcrAg levels are positively correlated with levels of serum HBV DNA and intrahepatic HBV DNA, but not with ALT [82, 83] . In particular, the HBcrAg level correlates well with the intrahepatic cccDNA level [84, 85] . Theoretically, the HBcrAg level is a good marker for HBV replication and reflects the transcriptional activity of cccDNA. The correlations are better in HBeAg-positive patients than in HBeAg-negative patients. Studies on the HBcrAg levels in the natural history of Asian and European CHB patients showed that HBcrAg is higher in the immune-tolerance and immune-clearance phases, followed by HBeAg-negative hepatitis, and lower in HBeAgnegative quiescent/inactive carrier phase [86, 87] . Patients with HBsAg seroclearance exhibit the lowest HBcrAg level. Interestingly, a portion of them still have detectable HBcrAg, suggesting its potential application in this group of patients [86] . Recently, HBcrAg has been found to predict the pathological status of liver tissues, including hepatic necroinflammation and advanced fibrosis. Moreover, using the Cox proportional hazards models, a hospital-based cohort study on 1031 treatment-naive CHB patients in Japan demonstrated that HBcrAg >2.9 log U/mL is independently associated with the incidence of HCC at an adjusted hazard ratio of 5.05 [88] .
Quantitative Anti-HBc Antibody
Anti-HBc antibody against HBcAg is a conventional serological marker of HBV infection. Immunoglobulin M (IgM) anti-HBc appears soon after acute HBV infection, and is followed by the appearance of immunoglobulin G (IgG) anti-HBc antibody, which indicates the prior exposure to HBV. Recently, a quantitative total anti-HBc (qAnti-HBc) has been developed, but its clinical utility has just begun to be explored [89] .
Previous studies showed that qAnti-HBc levels were positively correlated with ALT levels [90] [91] [92] [93] . Because ALT is generally considered an indicator of immune-mediated liver injury, this suggests that the qAnti-HBc level may reflect the immune response against HBV. Levels of qAnti-HBc were found to vary across different disease phases of HBV infection [91, 92] . Serum qAnti-HBc levels in the immune-clearance and reactivation phases were significantly higher than those in the immune-tolerance and inactive carrier phases. Interestingly, the qAnti-HBc levels were similar between patients in the immune-tolerant phase and inactive carriers, although the former had very high HBV DNA levels. Furthermore, HBsAg-positive patients had higher serum qAnti-HBc levels than HBsAg-negative individuals. Among HBsAg-negative individuals, subjects with occult HBV infection had higher serum qAnti-HBc levels than those with past HBV infection.
To summarize, distinct from current quantitative viral markers, total qAnti-HBc level may serve as a serological marker for HBV-induced liver inflammation. However, most of the current studies on qAnti-HBc are cross-sectional studies with small sample size. Therefore, the predictive value of the qAnti-HBc level in disease progression and clinical outcomes of CHB requires further investigation and validation in a larger longitudinal cohort.
Combinatorial Predictive Values of Viral Factors and Risk Scoring System
Given the complex clinical courses of chronic HBV infection, it is difficult to utilize a single viral factor to distinguish or predict different clinical outcomes. To more accurately delineate the different phases of CHB, a set of viral factors may be required to precisely identify the clinical status of patients. Accurately predicting the risk of cirrhosis and HCC is required for timely and appropriate treatment of CHB.
The need for a set of viral factors rather than a single one is exemplified by the development of several risk scoring systems that are utilized to predict the risk of HCC [94] [95] [96] [97] . Recently, the REACH-B (risk estimation for hepatocellular carcinoma in chronic hepatitis B) risk score, a 17-point risk scoring system, has also been developed by integrating several host and viral factors including age, sex, ALT level, HBeAg serostatus, and serum HBV DNA level. The REACH-B risk score was externally validated and shown to accurately predict the risk of HCC with a wide range, from 0.0% to 23.6% at 3 years, 0.0% to 47.4% at 5 years, and 0.0% to 81.6% at 10 years for patients with the lowest through the highest scores [98] . Later, the original REVEAL risk scoring system was further upgraded by incorporation of HBsAg level and internally validated [99] . This new risk calculator not only accurately predicts the risk of HCC, but also the risk of cirrhosis. The success of these scoring systems supports the utility of integration of a set of viral factors for identification of high-risk CHB patients.
Of note, although the REACH-B risk scores, as well as the other 2 scoring systems, CU-HCC (Chinese University-HCC) and GAG-HCC (guide with age, gender, HBV DNA, core promoter mutations and Cirrhosis-HCC), accurately predict the HCC risk of Asian patients [95, 96] , their performance of HCC risk prediction in Caucasian CHB patients is poor to moderate [100, 101] . In contrast, a newly developed PAGE-B (platelets, age, and gender) scoring system, which is based only on baseline patients' age, sex, and platelets, is a reliable predictive score for the 5-year HCC risk in Caucasian CHB patients treated by entecavir/tenofovir [102] . The differential predictive ability of different score systems indicates the effect of ethnic difference on scoring systems and the need to validate scoring systems in a large cohort composed of different populations.
CONCLUSIONS
Patients with chronic HBV infection exhibit a great variety of clinical outcomes. Accurate identification of patients at risk and timely intervention are critical to prevent the disease progression and the development of detrimental clinical outcomes. In addition, although the advance of current antiviral therapy including NA and interferon, chronic HBV infection still cannot be cured. Long-term antiviral therapy with NAs is often required due to the persistence of cccDNA. The benefit of long-term antiviral therapy should be balanced with the adverse effects of long-term use of antiviral agents. Identification of those who will benefit most from antiviral therapy is important.
With the advance of technology, several viral factors affecting the disease progression and clinical outcomes are identified. Integration of these viral factors may help to optimize patient screening and identify the patients at risk and allow timely intervention. 
